- The British Journal of Cancer has published a paper about the Phase II trial of Merrimack Pharmaceuticals' (MACK +5.2%) MM-398 drug for treating late-stage pancreatic cancer.
- The study met its primary endpoint, with 75% of patients surviving at least 3 months, including 25% who reached the one-year mark. The median overall survival was 5.2 months, while 50% of patients showed evidence of disease control.
- MM-398 is now in Phase III trials. (PR)
- Last week, SA author Ross Breckendridge noted that Merrimack's share price has been swinging significantly recently in response to interim clinical trial data from MM-121. Breckendridge believes that any downside "has been due to the misconception of the meaning of the data released, and a somewhat poor communication effort by the company."